Global bone marrow transplant market 2017-2021
About Bone Marrow Transplant
Bone marrow transplant is the medical procedure that is performed to replace the damaged or destroyed bone marrow due to infections, disease, or adverse effect of treatment. A normal bone marrow transplant includes transplantation of blood stem cell that travels to the bone marrow to produce new blood cell and thus improves growth of new marrow. When the bone marrow is damaged due to disease, allogeneic transplant is used whereas autologous transplant is used when bone marrow is intact at the start of disease but it gets damaged due to therapy.
Technavio’s analysts forecast the global bone marrow transplant market to grow at a CAGR of 5.39% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global bone marrow transplant market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.
The market is divided into the following segments based on geography:
Technavio Announces the Publication of its Research Report – Global Bone Marrow Transplant Market 2017-2021
Technavio recognizes the following companies as the key players in the global bone marrow transplant market: AllCells, Lonza, Merck, and Sanofi.
Other Prominent Vendors in the market are: Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences (a subsidiary of Medistem Panama).
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is growing number of registry. The number of the donor registry is increasing in recent times globally. Thus, the challenge of scarcity of donor can be fulfilled for future. The European Group for Blood and Marrow Transplant has started an initiative named Bone Marrow Donors Worldwide (BMDW) in which around 52 major countries across the globe have participated.”
According to the report, one driver in the market is technological advancement. The first transplant of bone marrow was carried out in 1956, and since then there have been tremendous improvements as far as technology is concerned. The advancement in technology has led to the more safer procedure and higher success rates of bone marrow transplant. This has improved the acceptance of this procedure, and the number of transplants has improved in recent years.
Further, the report states that one challenge in the market is scarcity of donors and its genetical acceptance. The supply and demand for bone marrow transplant are an imbalance, and it is one of the major challenges for this market. The demand of bone marrow transplant is increasing due to growing prevalence of the various chronic diseases such as cancer and blood-related disorders such as anemia. However, on the other side, the supply of bone marrow is poor due to lesser donors compared with the over-increasing demand.
AllCells, Lonza, Merck, Sanofi, Athersys, Beike Biotechnology, BioTime, bluebird bio, Caladrius, Cellular Biomedicine Group, Cellular Dynamics International, Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, CORESTEM, Gamida Cell, Global Stem Cells Group, Hemostemix, Histocell, Mesoblast, TiGenix, and Translational Biosciences